Peritoneovenous shunt in malignant ascites. The Bordet Institute experience from 1975-1998

Hepato-Gastroenterology

Volumn 47, Issue 35, 2000, Pages 1322-1324

  Tueche, S G ^a   Pector, J C ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Malignant ascites; Peritoneovenous shunt

Indexed keywords

ACETYLSALICYLIC ACID; ANTIPLASMIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR; DIPYRIDAMOLE; PLASMINOGEN ACTIVATOR; THROMBOCYTE FACTOR 3; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; FEMALE; HOSPITALIZATION; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; PERITONEAL CAVITY; PERITONEUM VEIN SHUNT; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SHUNTING; TERMINAL DISEASE; TREATMENT FAILURE;

ADULT; AGED; ASCITES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PERITONEOVENOUS SHUNT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033773709     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Malignant ascites. A comparison of peritoneovenous shunting and nonoperative management
2. Peritoneal mesothelioma
3. Peritoneo-venous shunting for ascites
4. Peritoneovenous shunting system for surgical management of ascites
5. Subcutaneous tumor growth complicating the positioning of Denver shunt intrapleural port-*-cath in mesothelioma patients
6. Vascular access problems
7. Coagulopathy post peritoneovenous shunt
8. Pulmonary tumor embolization after peritoneovenous shunting for malignant ascites